This Week in Cancer Discovery

Premium

In the newest issue of Cancer Discovery, researchers in the US and Spain report on the HIF-1α hypoxia response in tumor-infiltrating T lymphocytes. They found that CD8 and CD4 tumor-infiltrating T lymphocytes from colon carcinomas, melanomas, and spontaneous breast adenocarcinomas transplanted into mice are CD137-positive and that the expression of CD137 on activated T lymphocytes is enhanced by hypoxia and the prolyl-hydroxylase inhibitor dimethyloxalylglycine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.